Evidence that fibrinolytic changes in paediatric obesity translate into a hypofibrinolytic state: Relative contribution of TAFI and PAI-1

Thrombosis and Haemostasis

Volumn 108, Issue 2, 2012, Pages 311-317

  Semeraro, Fabrizio ^a   Giordano, Paola ^b   Faienza, Maria F ^b   Cavallo, Luciano ^b   Semeraro, Nicola ^a   Colucci, Mario ^a  

^a Sezione di Patologia Generale e Sperimentale   (Italy)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

Fibrinolytic capacity; PAI 1; TAFI; Thrombin; Thrombotic risk

Indexed keywords

CHOLESTEROL; D DIMER; FIBRINOGEN; FIBRINOLYTIC FACTOR; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLASMINOGEN ACTIVATOR INHIBITOR 1; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; THROMBIN ANTITHROMBIN COMPLEX; TRIACYLGLYCEROL;

ACTIVATED PROTEIN C RESISTANCE; ARTICLE; BLOOD CLOT LYSIS; BLOOD CLOTTING TIME; CHILD; CHILDHOOD OBESITY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD; SERUM SICKNESS;

BLOOD COAGULATION; BLOOD COAGULATION FACTORS; BLOOD COAGULATION TESTS; BODY MASS INDEX; CARBOXYPEPTIDASE U; CASE-CONTROL STUDIES; CHILD; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; MALE; OBESITY; PLASMINOGEN ACTIVATOR INHIBITOR 1; REGRESSION ANALYSIS;

EID: 84864365895     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH11-12-0864     Document Type: Article

References (42)

1. Cali AM, Caprio S. Obesity in children and adolescents. J Clin Endocrinol Metab 2008; 93 (Suppl 1): S31-36.
2. Daniels SR. The consequences of childhood overweight and obesity. Future Child 2006; 16: 47-67.
3. Faber DR, de Groot PG, Visseren FL. Role of adipose tissue in haemostasis, coagulation and fibrinolysis. Obes Rev 2009; 10: 554-563.
4. Mertens I, Van Gaal LF. Obesity, haemostasis and the fibrinolytic system. Obes Rev 2002; 3: 85-101.
5. Ferguson MA, Gutin B, Owens S, et al. Fat distribution and hemostatic measures in obese children. Am J Clin Nutr 1998; 67: 1136-1140.
6. Valle M, Gascón F, Martos R, et al. Infantile obesity: a situation of atherothrombotic risk? Metabolism 2000; 49: 672-675.
7. Estellés A, Dalmau J, Falcó C, et al. Plasma PAI-1 levels in obese children--effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost 2001; 86: 647-652.
8. Balagopal P, George D, Sweeten S, et al. Response of fractional synthesis rate (FSR) of fibrinogen, concentration of D-dimer and fibrinolytic balance to physical activity-based intervention in obese children. J Thromb Haemost 2008; 6: 1296-1303.
9. Mauras N, Delgiorno C, Kollman C, et al. Obesity without established comorbidities of the metabolic syndrome is associated with a proinflammatory and prothrombotic state, even before the onset of puberty in children. J Clin Endocrinol Metab 2010; 95: 1060-1068.
10. Aubert H, Frère C, Aillaud MF, et al. Weak and non-independent association between plasma TAFI antigen levels and the insulin resistance syndrome. J Thromb Haemost 2003; 1: 791-797.
11. Guven GS, Kiliçaslan A, Oz SG, et al. Decrements in the thrombin activatable fibrinolysis inhibitor (TAFI) levels in association with orlistat treatment in obesity. Clin Appl Thromb Hemost 2006; 12: 364-368.
12. Bajzar L. Thrombin activatable fibrinolysis inhibitor and an antifibrinolytic pathway. Arterioscler Thromb Vasc Biol 2000; 20: 2511-2518.
13. Mosnier LO, Bouma BN. Regulation of fibrinolysis by thrombin activatable fibrinolysis inhibitor, an unstable carboxypeptidase B that unites the pathways of coagulation and fibrinolysis. Arterioscler Thromb Vasc Biol 2006; 26: 2445-2453.
14. Cacciari E, Balsamo A, Palareti G, et al. Haemorheologic and fibrinolytic evaluation in obese children and adolescents. Eur J Pediatr 1988; 147: 381-384.
15. Cacciari E, Coccheri S, Bergamaschi R, et al. Hemostatic balance alterations in obese children. Acta Paediatr Scand 1982; 71: 479-484.
16. Cole TJ, Bellizzi MC, Flegal KM, et al. Establishing a standard definition for child overweight and obesity worldwide: International survey. Brit Med J 2000; 320: 1240-1243.
17. Giordano P, Del Vecchio GC, Cecinati V, et al. Metabolic, inflammatory, endothelial and haemostatic markers in a group of Italian obese children and adolescents. Eur J Pediatr 2011; 170: 845-850.
18. Colucci M, Binetti BM, Tripodi A, et al. Hyperprothrombinemia associated with prothrombin G20210A mutation inhibits plasma fibrinolysis through a TAFImediated mechanism. Blood 2004; 103: 2157-2161.
19. Bouma BN, Meijers JC. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). J Thromb Haemost 2003; 1: 1566-1574.
20. Bolliger D, Szlam F, Molinaro RJ, et al. Finding the optimal concentration range for fibrinogen replacement after severe haemodilution: an in vitro model. Br J Anaesth 2009; 102: 793-799.
21. Bajzar L, Nesheim ME, Tracy PB. The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent. Blood 1996; 88: 2093-2100.
22. Tosetto A, Missiaglia E, Gatto E, et al. The VITA project: phenotypic resistance to activated protein C and FV Leiden mutation in the general population. Vicenza Thrombophilia and Atherosclerosis. Thromb Haemost 1997; 78: 859-863.
23. Lowe GD, Rumley A, Woodward M, et al. Activated protein C resistance and the FV:R506Q mutation in a random population sample--associations with cardiovascular risk factors and coagulation variables. Thromb Haemost 1999; 81: 918-924.
24. Landin K, Stigendal L, Eriksson E, et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism 1990; 39: 1044-1048.
25. Skurk T, Hauner H. Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. Int J Obes Relat Metab Disord 2004; 28: 1357-1364.
26. Lisman T, Leebek FWG, Mosnier LO, et al. Thrombin activatable fibrinolysis inhibitor deficiency in cirrhosis is not associated with increased plasma fibrinolysis. Gastroenterology 2001; 121: 131-139.
27. Rijken DC, Hoegee-De Nobel E, Jie AFH, et al. Development of a new test for the global fibrinolytic capacity in whole blood. J Thromb Haemost 2008; 6: 151-157.
28. Lisman T, de Groot PG, Meijers JC, et al. Reduced plasma fibrinolytic potential is a risk factor for venous thrombosis. Blood 2005; 105: 1102-1105.
29. Leurs J, Wissing BM, Nerme V, et al. Different mechanisms contribute to the biphasic pattern of carboxypeptidase U (TAFIa) generation during in vitro clot lysis in human plasma. Thromb Haemost 2003; 89: 264-271.
30. Ammollo CT, Semeraro F, Incampo F, et al. Dabigatran enhances clot susceptibility to fibrinolysis by mechanisms dependent on and independent of thrombinactivatable fibrinolysis inhibitor. J Thromb Haemost 2010; 8: 790-798.
31. Leiden. J Biol Chem 1996; 271: 22949-22952.
32. Colucci M, Simioni P, Piro D, et al. An antifibrinolytic effect associated with an anti-factor V antibody in a patient with severe thrombophilia. Haematologica 2003; 88: 1383-1389.
33. Binetti BM, Rotunno C, Tripodi A, et al. Hyperprothrombinaemia-induced APC resistance: differential influence on fibrin formation and fibrinolysis. Thromb Haemost 2006; 95: 606-611.
34. Solá E, Vayá A, Villa P, et al. Obesity and activated protein C resistance. Pathophysiol Haemost Thromb 2008; 36: 64-68.
35. Broze GJ Jr. Thrombin-dependent inhibition of fibrinolysis. Curr Opin Hematol 1996; 3: 390-394.
36. Von dem Borne PA, Bajzar L, Meijers JC, et al. Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis. J Clin Invest 1997; 99: 2323-2327.
37. Pomp ER, le Cessie S, Rosendaal FR, et al. Risk of venous thrombosis: obesity and its joint effect with oral contraceptive use and prothrombotic mutations. Br J Haematol 2007; 139: 289-296.
38. Allman-Farinelli MA. Obesity and venous thrombosis: a review. Semin Thromb Hemost 2011; 37: 903-907.
39. Vu LT, Nobuhara KK, Lee H, et al. Determination of risk factors for deep venous thrombosis in hospitalized children. J Pediatr Surg 2008; 43: 1095-1099.
40. Rana AR, Michalsky MP, Teich S, et al. Childhood obesity: a risk factor for injuries observed at a level-1 trauma center. J Pediatr Surg 2009; 44: 1601-1605.
41. Guimarães AH, de Bruijne EL, Lisman T, et al. Hypofibrinolysis is a risk factor for arterial thrombosis at young age. Br J Haematol 2009; 145: 115-120.
42. Pankiw-Bembenek O, Zalewski J, Goralczyk T, et al. A history of early stent thrombosis is associated with prolonged clot lysis time. Thromb Haemost 2012: 107: 513-520.